Unsubscribe Parkinson's

At 03:38 PM 5/27/98 -0400, you wrote:
>There are 17 messages totalling 1196 lines in this issue.
>
>Topics in this special issue:
>
>  1. falling (2)
>  2. What's Really Important
>  3. news
>  4. importand news
>  5. Zoloft Experience? (2)
>  6. Petitions still available (2)
>  7. Eye-problems
>  8. imipramine (2)
>  9. towards an understanding of falling (3)
> 10. LOOKING FOR JERRY FINCH
> 11. PubMed search results - PD - 30 days  [1 of 2]
>
>----------------------------------------------------------------------
>
>Date:    Wed, 27 May 1998 11:35:56 EDT
>From:    DPYOTHERS <[log in to unmask]>
>Subject: Re: falling
>
>Dear falling,
>I just had a fall last week, from the family room to the garage, two steps and
>I have a handle to hold too, but down I went.  It's doing things too quickly
>and I was  in a hurry that day.  I'm on Sinemet CR and Requip and have a hard
>time with baalance and worrying about that next fall.  I  forget I have to
>tell my feet to move, right-right-right.
>
>Patricia
>61, 4 yrs.
>
>------------------------------
>
>Date:    Wed, 27 May 1998 11:43:02 -0400
>From:    Gail Vass <[log in to unmask]>
>Subject: What's Really Important
>
>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
>               What's Really Important
>
>     A few years ago at the Seattle Special Olympics, nine
>contestants, all physically or mentally disabled, assembled
>at the starting line for the 100-yard dash. At the gun they
>all started out, not exactly in a dash, but with the relish
>to run the race to the finish and win.
>     All, that is, except one boy who stumbled on the asphalt,
>tumbled over a couple of times, and began to cry. The other
>eight heard the boy cry. They slowed down and paused. Then
>they all turned around and went back. Every one of them. One
>girl with Down's syndrome bent down and kissed him and said,
>"This will make it better." Then all nine linked arms and
>walked together to the finish line.
>      Everyone in the stadium stood, and the cheering went
>on for 10 minutes.
>
>                  By Author Unknown
>                     Submitted by Bob French
>                     from A 3rd Serving of Chicken Soup for the Soul
>                     Copyright 1996 by Jack Canfield and
>                     Mark Victor Hansen
>
>A good reminder,
>
>Gail Vass
>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
>
>------------------------------
>
>Date:    Wed, 27 May 1998 11:42:32 EDT
>From:    DeitzM <[log in to unmask]>
>Subject: news
>
>This is a multi-part message in MIME format.
>
>--part0_896283752_boundary
>Content-ID: <[log in to unmask]>
>Content-type: text/plain; charset=US-ASCII
>
>
>NEOTROFIN Reported to Stimulate Nerve Regeneration
>
>    IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics,  Inc.
>(Nasdaq: NEOT; NEOTW) announced today that researchers from  North Carolina
>and Canada reported that the Company's lead product  candidate, AIT-082
>(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue
>culture and in animals.
>
>    At the 6th International Symposium on Adenosine and Adenine  Nucleotides,
>held in Ferrara, Italy, Dr.  Bernhard H.J.  Juurlink of  the Department of
>Anatomy and Cell Biology at the University of  Saskatchewan, Saskatoon,
>Saskatchewan, Canada, reported that  treatment of hippocampal neurons with
>AIT-082 caused nerve outgrowth  and enhanced branching of the nerve processes.
>Hippocampal neurons  have been reported to be involved in memory function.
>
>    "Glutamate excitotoxicity is implicated in a number of  neurodegenerative
>diseases,"  Dr.  Juurlink stated.  "AIT-082 is  potentially therapeutic in a
>number of neurodegenerative disorders.   We have demonstrated in hippocampal
>neurons grown in culture that  AIT-082 not only promotes neurite formation in
>developing hippocampal neurons, but it prevents much of the neurite
>degeneration following  exposure to excessive amounts of the neurotransmitter
>glutamate."
>
>    Dr.  Julio J.  Ramirez, the R.  Stuart Dickson Professor of  Psychology,
>Davidson College, Davidson, North Carolina, demonstrated  in animals that
>after destruction of a discreet area of the brain  involved in memory,
>treatment with AIT-082 caused re-growth of  neurons into the damaged area.
>These effects were seen after only  four days of treatment with AIT-082.
>
>    "Since the reorganization of brain circuitry has been shown to  contribute
>to recovery of memory function after injury or  degeneration in areas crucial
>to learning and memory,"  Dr.  Ramirez  stated, "the possibility that AIT-082
>might enhance this  reorganization opens up marvelous opportunities to promote
>recovery  of function in injured and diseased brains."
>
>    NeoTherapeutics is engaged in the discovery and development of  drugs that
>act on the central nervous system to repair nerve cells  and treat
>neurodegenerative diseases such as Alzheimer's disease,  spinal cord injury,
>Parkinson's disease and stroke, as well as other  neurological conditions such
>as migraine.  NeoTherapeutics' products  are orally administered and based
>upon patented technologies.   AIT-082 (NEOTROFIN(tm)) is currently in human
>clinical trials for the treatment of Alzheimer's disease.  For additional
>company  information, visit the NeoTherapeutics website at
>www.neotherapeutics.com.
>
>    This press release contains forward-looking statements regarding  future
>events and the future performance of NeoTherapeutics that  involve risks and
>uncertainties that could cause actual results to  differ materially.  These
>risks include, but are not limited to, the  biological activity, side effect
>profile and efficacy of AIT-082, the early stage of product development, the
>potential need for additional funding, the initiation and completion of
>clinical trials and  dependence on third parties for clinical testing,
>manufacturing and  marketing.  These risks are described in further detail in
>the  Company's annual and quarterly reports filed with the Securities and
>Exchange Commission.
>
>--part0_896283752_boundary
>Content-ID: <[log in to unmask]>
>Content-type: message/rfc822
>Content-transfer-encoding: 7bit
>Content-disposition: inline
>
>From: Gregfmason <[log in to unmask]>
>Return-path: <[log in to unmask]>
>To: [log in to unmask]
>Subject: PD Stuff
>Date: Wed, 27 May 1998 02:22:59 EDT
>Organization: AOL (http://www.aol.com)
>Mime-Version: 1.0
>Content-type: text/plain; charset=US-ASCII
>Content-transfer-encoding: 7bit
>
>Subj:   NEOTROFIN Reported to Stimulate Nerve Regeneration
>Date:   98-05-21 10:09:30 EDT
>From:   AOL News
>BCC:    Gregfmason
>
>NEOTROFIN Reported to Stimulate Nerve Regeneration
>
>    IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics,  Inc.
>(Nasdaq: NEOT; NEOTW) announced today that researchers from  North Carolina
>and Canada reported that the Company's lead product  candidate, AIT-082
>(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue
>culture and in animals.
>
>    At the 6th International Symposium on Adenosine and Adenine  Nucleotides,
>held in Ferrara, Italy, Dr.  Bernhard H.J.  Juurlink of  the Department of
>Anatomy and Cell Biology at the University of  Saskatchewan, Saskatoon,
>Saskatchewan, Canada, reported that  treatment of hippocampal neurons with
>AIT-082 caused nerve outgrowth  and enhanced branching of the nerve processes.
>Hippocampal neurons  have been reported to be involved in memory function.
>
>    "Glutamate excitotoxicity is implicated in a number of  neurodegenerative
>diseases,"  Dr.  Juurlink stated.  "AIT-082 is  potentially therapeutic in a
>number of neurodegenerative disorders.   We have demonstrated in hippocampal
>neurons grown in culture that  AIT-082 not only promotes neurite formation in
>developing hippocampal neurons, but it prevents much of the neurite
>degeneration following  exposure to excessive amounts of the neurotransmitter
>glutamate."
>
>    Dr.  Julio J.  Ramirez, the R.  Stuart Dickson Professor of  Psychology,
>Davidson College, Davidson, North Carolina, demonstrated  in animals that
>after destruction of a discreet area of the brain  involved in memory,
>treatment with AIT-082 caused re-growth of  neurons into the damaged area.
>These effects were seen after only  four days of treatment with AIT-082.
>
>    "Since the reorganization of brain circuitry has been shown to  contribute
>to recovery of memory function after injury or  degeneration in areas crucial
>to learning and memory,"  Dr.  Ramirez  stated, "the possibility that AIT-082
>might enhance this  reorganization opens up marvelous opportunities to promote
>recovery  of function in injured and diseased brains."
>
>    NeoTherapeutics is engaged in the discovery and development of  drugs that
>act on the central nervous system to repair nerve cells  and treat
>neurodegenerative diseases such as Alzheimer's disease,  spinal cord injury,
>Parkinson's disease and stroke, as well as other  neurological conditions such
>as migraine.  NeoTherapeutics' products  are orally administered and based
>upon patented technologies.   AIT-082 (NEOTROFIN(tm)) is currently in human
>clinical trials for the treatment of Alzheimer's disease.  For additional
>company  information, visit the NeoTherapeutics website at
>www.neotherapeutics.com.
>
>    This press release contains forward-looking statements regarding  future
>events and the future performance of NeoTherapeutics that  involve risks and
>uncertainties that could cause actual results to  differ materially.  These
>risks include, but are not limited to, the  biological activity, side effect
>profile and efficacy of AIT-082, the early stage of product development, the
>potential need for additional funding, the initiation and completion of
>clinical trials and  dependence on third parties for clinical testing,
>manufacturing and  marketing.  These risks are described in further detail in
>the  Company's annual and quarterly reports filed with the Securities and
>Exchange Commission.
>
>--part0_896283752_boundary--
>
>------------------------------
>
>Date:    Wed, 27 May 1998 11:44:38 EDT
>From:    DeitzM <[log in to unmask]>
>Subject: importand news
>
>This is a multi-part message in MIME format.
>
>--part0_896283878_boundary
>Content-ID: <[log in to unmask]>
>Content-type: text/plain; charset=US-ASCII
>
>
>NEOTROFIN Reported to Stimulate Nerve Regeneration
>
>    IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics,  Inc.
>(Nasdaq: NEOT; NEOTW) announced today that researchers from  North Carolina
>and Canada reported that the Company's lead product  candidate, AIT-082
>(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue
>culture and in animals.
>
>    At the 6th International Symposium on Adenosine and Adenine  Nucleotides,
>held in Ferrara, Italy, Dr.  Bernhard H.J.  Juurlink of  the Department of
>Anatomy and Cell Biology at the University of  Saskatchewan, Saskatoon,
>Saskatchewan, Canada, reported that  treatment of hippocampal neurons with
>AIT-082 caused nerve outgrowth  and enhanced branching of the nerve processes.
>Hippocampal neurons  have been reported to be involved in memory function.
>
>    "Glutamate excitotoxicity is implicated in a number of  neurodegenerative
>diseases,"  Dr.  Juurlink stated.  "AIT-082 is  potentially therapeutic in a
>number of neurodegenerative disorders.   We have demonstrated in hippocampal
>neurons grown in culture that  AIT-082 not only promotes neurite formation in
>developing hippocampal neurons, but it prevents much of the neurite
>degeneration following  exposure to excessive amounts of the neurotransmitter
>glutamate."
>
>    Dr.  Julio J.  Ramirez, the R.  Stuart Dickson Professor of  Psychology,
>Davidson College, Davidson, North Carolina, demonstrated  in animals that
>after destruction of a discreet area of the brain  involved in memory,
>treatment with AIT-082 caused re-growth of  neurons into the damaged area.
>These effects were seen after only  four days of treatment with AIT-082.
>
>    "Since the reorganization of brain circuitry has been shown to  contribute
>to recovery of memory function after injury or  degeneration in areas crucial
>to learning and memory,"  Dr.  Ramirez  stated, "the possibility that AIT-082
>might enhance this  reorganization opens up marvelous opportunities to promote
>recovery  of function in injured and diseased brains."
>
>    NeoTherapeutics is engaged in the discovery and development of  drugs that
>act on the central nervous system to repair nerve cells  and treat
>neurodegenerative diseases such as Alzheimer's disease,  spinal cord injury,
>Parkinson's disease and stroke, as well as other  neurological conditions such
>as migraine.  NeoTherapeutics' products  are orally administered and based
>upon patented technologies.   AIT-082 (NEOTROFIN(tm)) is currently in human
>clinical trials for the treatment of Alzheimer's disease.  For additional
>company  information, visit the NeoTherapeutics website at
>www.neotherapeutics.com.
>
>    This press release contains forward-looking statements regarding  future
>events and the future performance of NeoTherapeutics that  involve risks and
>uncertainties that could cause actual results to  differ materially.  These
>risks include, but are not limited to, the  biological activity, side effect
>profile and efficacy of AIT-082, the early stage of product development, the
>potential need for additional funding, the initiation and completion of
>clinical trials and  dependence on third parties for clinical testing,
>manufacturing and  marketing.  These risks are described in further detail in
>the  Company's annual and quarterly reports filed with the Securities and
>Exchange Commission.
>
>--part0_896283878_boundary
>Content-ID: <[log in to unmask]>
>Content-type: message/rfc822
>Content-transfer-encoding: 7bit
>Content-disposition: inline
>
>From: Gregfmason <[log in to unmask]>
>Return-path: <[log in to unmask]>
>To: [log in to unmask]
>Subject: PD Stuff
>Date: Wed, 27 May 1998 02:22:59 EDT
>Organization: AOL (http://www.aol.com)
>Mime-Version: 1.0
>Content-type: text/plain; charset=US-ASCII
>Content-transfer-encoding: 7bit
>
>Subj:   NEOTROFIN Reported to Stimulate Nerve Regeneration
>Date:   98-05-21 10:09:30 EDT
>From:   AOL News
>BCC:    Gregfmason
>
>NEOTROFIN Reported to Stimulate Nerve Regeneration
>
>    IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics,  Inc.
>(Nasdaq: NEOT; NEOTW) announced today that researchers from  North Carolina
>and Canada reported that the Company's lead product  candidate, AIT-082
>(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue
>culture and in animals.
>
>    At the 6th International Symposium on Adenosine and Adenine  Nucleotides,
>held in Ferrara, Italy, Dr.  Bernhard H.J.  Juurlink of  the Department of
>Anatomy and Cell Biology at the University of  Saskatchewan, Saskatoon,
>Saskatchewan, Canada, reported that  treatment of hippocampal neurons with
>AIT-082 caused nerve outgrowth  and enhanced branching of the nerve processes.
>Hippocampal neurons  have been reported to be involved in memory function.
>
>    "Glutamate excitotoxicity is implicated in a number of  neurodegenerative
>diseases,"  Dr.  Juurlink stated.  "AIT-082 is  potentially therapeutic in a
>number of neurodegenerative disorders.   We have demonstrated in hippocampal
>neurons grown in culture that  AIT-082 not only promotes neurite formation in
>developing hippocampal neurons, but it prevents much of the neurite
>degeneration following  exposure to excessive amounts of the neurotransmitter
>glutamate."
>
>    Dr.  Julio J.  Ramirez, the R.  Stuart Dickson Professor of  Psychology,
>Davidson College, Davidson, North Carolina, demonstrated  in animals that
>after destruction of a discreet area of the brain  involved in memory,
>treatment with AIT-082 caused re-growth of  neurons into the damaged area.
>These effects were seen after only  four days of treatment with AIT-082.
>
>    "Since the reorganization of brain circuitry has been shown to  contribute
>to recovery of memory function after injury or  degeneration in areas crucial
>to learning and memory,"  Dr.  Ramirez  stated, "the possibility that AIT-082
>might enhance this  reorganization opens up marvelous opportunities to promote
>recovery  of function in injured and diseased brains."
>
>    NeoTherapeutics is engaged in the discovery and development of  drugs that
>act on the central nervous system to repair nerve cells  and treat
>neurodegenerative diseases such as Alzheimer's disease,  spinal cord injury,
>Parkinson's disease and stroke, as well as other  neurological conditions such
>as migraine.  NeoTherapeutics' products  are orally administered and based
>upon patented technologies.   AIT-082 (NEOTROFIN(tm)) is currently in human
>clinical trials for the treatment of Alzheimer's disease.  For additional
>company  information, visit the NeoTherapeutics website at
>www.neotherapeutics.com.
>
>    This press release contains forward-looking statements regarding  future
>events and the future performance of NeoTherapeutics that  involve risks and
>uncertainties that could cause actual results to  differ materially.  These
>risks include, but are not limited to, the  biological activity, side effect
>profile and efficacy of AIT-082, the early stage of product development, the
>potential need for additional funding, the initiation and completion of
>clinical trials and  dependence on third parties for clinical testing,
>manufacturing and  marketing.  These risks are described in further detail in
>the  Company's annual and quarterly reports filed with the Securities and
>Exchange Commission.
>
>--part0_896283878_boundary--
>
>------------------------------
>
>Date:    Wed, 27 May 1998 11:44:51 EDT
>From:    DPYOTHERS <[log in to unmask]>
>Subject: Re: Zoloft Experience?
>
>Ron:
>I have been taking Zoloft for some time now, 150 mg.  It does help the blues
>but makes things steady and non committal feelings abound, but sometimes you
>need that.
>
>Patricia
>
>61,4 yrs.
>
>------------------------------
>
>Date:    Wed, 27 May 1998 11:47:01 EDT
>From:    KMCRAE <[log in to unmask]>
>Subject: Re: Zoloft Experience?
>
>Ken has been taking zoloft for several years with no noticeable side effects.
>I t does seem to hold his tendency to depression in check.  Barbara Smith,
>CG/Ken/70/17
>
>------------------------------
>
>Date:    Wed, 27 May 1998 11:55:59 EDT
>From:    DeitzM <[log in to unmask]>
>Subject: Petitions still available
>
>Do you have your petitons? If not send via email name and home address and it
>will be in the next mail.
>
>
>Helen Mason        [log in to unmask]
>
>------------------------------
>
>Date:    Wed, 27 May 1998 12:02:13 -0500
>From:    MRS BEV K STEWARD <[log in to unmask]>
>Subject: Re: falling
>
>Barb,
>
>Have you been to a neurologist who is a movement specialist?  If not,
>I'd sure recommend it in order to pin down the possibility of a
>Parkinson Plus sydrome.  (closely related but not PD).
>
>Bev
>
>------------------------------
>
>Date:    Wed, 27 May 1998 17:10:36 UT
>From:    Barbara Mallut <[log in to unmask]>
>Subject: Re: Eye-problems
>
>Camilla, and All...
>
>The good news and the bad news:
>
>First the good news:
>
>Taking the "PD eye problem" a bit further, our List-sis,
>Gail Vass, had emailed me a copy of a message
>posted on the Sjogren's Syndrome List with the best
>eye-drop-advice I've had yet.
>
>FYI... Sjogren's Syndrome is an arthritis-related
>Autoimmune disease that effects the eyes terribly!  If
>ANYONE knows about eyes and disease-caused eye
>problems, it's Sjogren's suffers!
>
>The Sjogren's-list-folks recommend the use of
>"Refresh Plus" lubricant eye drops made by
>Allergan, which has NO PRESERVATIVES.  This
>last NON-ingredient is very important as far as your
>comfort level and unfortunately, it seems all over-
>the-counter eye drops DO have preservatives
>EXCEPT for the "Refresh Plus" brand.
>
>The reason this brand can omit preservatives is
>because EACH dose of  eye drops is individually
>packaged in single-dose, disposable plastic container.
>THAT makes a world of difference in your comfort
>level and your eyes'll thank ya for it 'cause they'll feel
>SOOOO good after a shot of Refresh Plus  - I'm using
> the product now and it's GREAT!  TOTAL eye comfort!
>
>The bad news:
>
>Thirty individually packaged doses of Refresh plus
>(one box of 30) cost $9.95!  I use eye drops twice
>a day, minimum (used 'em much MORE prior to
>changing over to the Refresh Plus product), and this
>is just beyond my means on an ongoing basis.
>I suspect most other PWPs will feel the same
>about the cost.
>
>More "bad news"
>
>I don't happen to have a tremor so it's not TOO tough
>for me to pick up, hold, and squeeze the smallish
>individual-dose Fresh Plus containers.  However, I
>can easily see where a Parkie WITH a tremor coming
>close to putting an eye out trying to hold and squeeze
>those small individual-dose containers.
>
>NONE-THE-LESS... this product DOES bring
>SIGNIFICANT relief to painful, stinging ,oh-so-dry
>eyes, so IF ya can, I'd suggest trying it.
>
>Barb Mallut
>[log in to unmask]
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>----------
>From:   Parkinson's Information Exchange on behalf of Camilla H.Flintermann
>Sent:   Wednesday, May 27, 1998 7:40 AM
>To:     Multiple recipients of list PARKINSN
>Subject:        Re: Eye-problems
>
>YES!  this, or a variation "eye scrub" of the lids, is standard RX for the
>blepharitis that plagues PWPs. Peter has also found it helpful, and we try
>to remember to use "artificial tears" As drops a few times a day to combat
>the dryness.
>
>
>
>>on the advice of my eye doctor, several times a day, i add a few drops of
>>BABY shampoo to a cup of warm water and soak my eyes with a tissue that
>>has been dipped into the solution.,,  been doing it for over a year...
>> all i have to do is get complacent and skip a few days and the crusties
>>and potential for an irritating stie return... it may help others as well.
>>
>>
>>
>>Dale Williams
>>[log in to unmask]
>
>
>  Camilla Flintermann, CG for Peter 80/9
>  Oxford, OH
>  [log in to unmask]
>"http://www.newcountry.nu/pd/members/camilla/one.htm" My Home Page
>
>                 * * * * * * * * * * * * * * * * *
>                 * Ask me about the CARE list for*
>                 *   Parkinson's caregivers !    *
>                 * * * * * * * * * * * * * * * * *
>
>------------------------------
>
>Date:    Wed, 27 May 1998 10:02:36 -0700
>From:    Jim Jameson <[log in to unmask]>
>Subject: imipramine
>
>I take 20mg in the morning and 20mg at night of imipramine, for depression
>and have not seen much relief except it seems to keep me tired all the
>time.
>I keep hearing about zoloft does anyone know if that is better and makes
>you less
>tired all the time.
>also I have been on amantadine for four months and it seems to help with
>the
>tremors a slight amount. I take 10mg in the morning and 10 at night. I have
>been
>on sinemet for four years at max dose twice a day have never seen much for
>that
>one.  I also take selegelline twice a day.. the only thing that has shown
>me anything
>is this amantadine. I use to take permax however it almost shut down my
>kidneys..
>Does anyone have better suggestions?
>
>Jim J.  54/4
>[log in to unmask]
>
>P.S. I love all the information on the list
>
>------------------------------
>
>Date:    Wed, 27 May 1998 13:17:06 -0400
>From:    Tom Riess <[log in to unmask]>
>Subject: towards an understanding of falling
>
>Dear Barbara,
>
>You said you were unclear as to whether festination is a symptom of PD or=
> a
>side effect of the meds.
>
>This is unclear to everyone  but let me offer my opinion.  Festination li=
>ke
>dyskinesia is not a side effect of medication but rather is a symptom of
>basic PD pathology  which is manifested in the presence of exogenous
>dopamine.  Furthermore, this pathology is actually a visual perceptive or=
>
>vision processing problem.  The same pathology in the absence of dopamine=
> =
>
>manifests itself as akinesia.  So I would speculate that akinesia and
>dyskinesia are two sides of the same coin and the side that is "up" is a
>function of medication level. Manipulating various parameters of vision c=
>an
>impact on akinesia, dyskinesia and festination and ultimately falling as
>well.
>
>regards,
>
>Tom
>
>------------------------------
>
>Date:    Wed, 27 May 1998 13:22:34 EDT
>From:    Elizabeth Southwood <[log in to unmask]>
>Subject: Re: LOOKING FOR JERRY FINCH
>
>I've emailed Jerry Finch ([log in to unmask]) and not had any answer re changes in
>my website as requested but the emails have not been returned.  Liz S~~
>
>------------------------------
>
>Date:    Wed, 27 May 1998 13:39:59 -0400
>From:    Gail Vass <[log in to unmask]>
>Subject: Re: imipramine
>
>Jim,
>Have you been seen by a Movement Disorder Specialist who specializes in
>Parkinsons and have your meds evaluated by them?
>Your cyber sis,
>Gail Vass email address [log in to unmask]
>
>------------------------------
>
>Date:    Wed, 27 May 1998 12:27:47 -0600
>From:    Nancy Burnham <[log in to unmask]>
>Subject: Re: Petitions still available
>
>Received my copy yesterday.  When do you need them back?  Nancy B
>-----Original Message-----
>From: DeitzM <[log in to unmask]>
>To: Multiple recipients of list PARKINSN <[log in to unmask]>
>Date: Wednesday, May 27, 1998 10:00 AM
>Subject: Petitions still available
>
>
>>Do you have your petitons? If not send via email name and home address and
>it
>>will be in the next mail.
>>
>>
>>Helen Mason        [log in to unmask]
>>
>
>------------------------------
>
>Date:    Wed, 27 May 1998 15:20:42 EDT
>From:    William Heitman <[log in to unmask]>
>Subject: Re: towards an understanding of falling
>
>In a message dated 5/27/98 12:22:19 PM Central Daylight Time,
>[log in to unmask] writes:
>
><<
> You said you were unclear as to whether festination is a symptom of PD or a
> side effect of the meds.
>  >>
>I believe Dr Parkinson described a patient who hired a guy to walk ahead of
>him and stop him when he got to going too fast.  If so, that patient was
>festinating long before the advent of L-Dopa therapy.  I am almost certain
>that it is a function of the disease.
>
>Regards,
>WHH 54/18
>
>------------------------------
>
>Date:    Wed, 27 May 1998 15:24:23 EDT
>From:    Krishna Ayala <[log in to unmask]>
>Subject: Re: towards an understanding of falling
>
>Dear Tom,
>
>I found your opinion regarding akinesia and dyskinesia as connected with
>vision rather interesting. You say you could use your visual perceptions
>to control dyskinesia and akinesia.
>
>Could you be more specific as to how one can use our visual perceptions
>to control dyskinesia?
>
>regards
>kris
>
>e-mail [log in to unmask]
>
>
>______________________________________________________
>Get Your Private, Free Email at http://www.hotmail.com
>
>------------------------------
>
>Date:    Wed, 27 May 1998 15:38:09 EDT
>From:    Janet Paterson <[log in to unmask]>
>Subject: PubMed search results - PD - 30 days  [1 of 2]
>
>Parkinson's Disease - 164 citations found - 98/05/27 - 30 days - PubMed
>
> Spillantini MG, et al.
>alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's
>disease and dementia with Lewy bodies.
>Proc Natl Acad Sci U S A. 1998 May 26; 95(11): 6469-6473.
>PMID: 9600990.
>
> Wakabayashi K, et al.
>Apolipoprotein E epsilon4 allele and progression of cortical Lewy body
>pathology in Parkinson's disease.
>Acta Neuropathol (Berl). 1998 May; 95(5): 450-454.
>PMID: 9600590; UI: 98261217.
>
> Good PF, et al.
>Protein nitration in Parkinson's disease.
>J Neuropathol Exp Neurol. 1998 Apr; 57(4): 338-342.
>PMID: 9600227; UI: 98260854.
>
> Irizarry MC, et al.
>Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's
>disease and cortical Lewy body disease contain alpha-synuclein
>immunoreactivity.
>J Neuropathol Exp Neurol. 1998 Apr; 57(4): 334-337.
>PMID: 9600226; UI: 98260853.
>
> Hansen LA, et al.
>Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's
>disease and dementia.
>J Neurol Neurosurg Psychiatry. 1998 May; 64(5): 653-656.
>PMID: 9598683; UI: 98258630.
>
> Colzi A, et al.
>Continuous subcutaneous waking day apomorphine in the long term treatment of
>levodopa induced interdose dyskinesias in Parkinson's disease.
>J Neurol Neurosurg Psychiatry. 1998 May; 64(5): 573-576.
>PMID: 9598668; UI: 98258615.
>
> Liu EH, et al.
>Persistent perioperative laryngospasm in a patient with Parkinson's disease.
>Can J Anaesth. 1998 May; 45(5 Pt 1): 495. No abstract available.
>PMID: 9598268; UI: 98260630.
>
> Uitti RJ.
>Medical treatment of essential tremor and Parkinson's disease.
>Geriatrics. 1998 May; 53(5): 46-48.
>PMID: 9597979; UI: 98260270.
>
> Uitti RJ.
>Tremor: how to determine if the patient has Parkinson's disease.
>Geriatrics. 1998 May; 53(5): 30-36.
>PMID: 9597978; UI: 98260269.
>
> Quinn N, et al.           
>Functional neurosurgery for Parkinson's disease. Has come a long way, though
>much remains experimental.
>BMJ. 1998 Apr 25; 316(7140): 1259-1260. No abstract available.
>PMID: 9554893; UI: 98223565.
>
> Davidson WS, et al.           
>Stabilization of alpha-synuclein secondary structure upon binding to synthetic
>membranes.
>J Biol Chem. 1998 Apr 17; 273(16): 9443-9449.
>PMID: 9545270; UI: 98211967.
>
> Cadet JL, et al.
>Free radicals and the pathobiology of brain dopamine systems.
>Neurochem Int. 1998 Feb; 32(2): 117-131. Review.
>PMID: 9542724; UI: 98203852.
>
> Factor SA, et al.           
>'Sleep benefit' in Parkinson's disease.
>Neurology. 1998 May; 50(5): 1514-1515. No abstract available.
>PMID: 9596032; UI: 98255471.
>
> Checkoway H, et al.           
>A genetic polymorphism of MAO-B modifies the association of cigarette smoking
>and Parkinson's disease.
>Neurology. 1998 May; 50(5): 1458-1461.
>PMID: 9596006; UI: 98255445.
>
> Factor SA, et al.           
>Acute delirium after withdrawal of amantadine in Parkinson's disease.
>Neurology. 1998 May; 50(5): 1456-1458.
>PMID: 9596005; UI: 98255444.
>
> Gorell JM, et al.           
>The risk of Parkinson's disease with exposure to pesticides, farming, well
>water, and rural living.
>Neurology. 1998 May; 50(5): 1346-1350.
>PMID: 9595985; UI: 98255424.
>
> Hogl BE, et al.           
>A clinical, pharmacologic, and polysomnographic study of sleep benefit in
>Parkinson's disease.
>Neurology. 1998 May; 50(5): 1332-1339.
>PMID: 9595983; UI: 98255422.
>
> Growdon JH, et al.           
>Levodopa improves motor function without impairing cognition in mild non-
>demented Parkinson's disease patients. Parkinson Study Group.
>Neurology. 1998 May; 50(5): 1327-1331.
>PMID: 9595982; UI: 98255421.
>
> Verhagen Metman L, et al.           
>Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's
>disease.
>Neurology. 1998 May; 50(5): 1323-1326.
>PMID: 9595981; UI: 98255420.
>
> Goetz CG.           
>New lessons from old drugs: amantadine and Parkinson's disease.
>Neurology. 1998 May; 50(5): 1211-1212. No abstract available.
>PMID: 9595964; UI: 98255403.
>
> Greene SM, et al.           
>Symptom study in context: effects of marital quality on signs of Parkinson's
>disease during patient-spouse interaction.
>Psychiatry. 1998; 61(1): 35-45.
>PMID: 9595594; UI: 98257950.
>
> Castro ME, et al.           
>5-HT1B receptor binding in degenerative movement disorders.
>Brain Res. 1998 Apr 20; 790(1-2): 323-328.
>PMID: 9593971.
>
> Schapira AHV.           
>Human complex I defects in neurodegenerative diseases.
>Biochim Biophys Acta. 1998 May 6; 1364(2): 261-270.
>PMID: 9593927.
>
> Walker DG, et al.           
>Expression of the proto-oncogene Ret, a component of the GDNF receptor
>complex, persists in human substantia nigra neurons in Parkinson's disease.
>Brain Res. 1998 May 11; 792(2): 207-217.
>PMID: 9593897.
>
> Gomez-Vargas M, et al.           
>Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and
>inhibits lipid peroxidation in different regions of the rat brain.
>Brain Res. 1998 Apr 20; 790(1-2): 202-208.
>PMID: 9593894.
>
> Van Muiswinkel FL, et al.           
>Sustained pharmacological inhibition of nitric oxide synthase does not affect
>the survival of intrastriatal rat fetal mesencephalic transplants.
>Brain Res. 1998 May 4; 792(1): 48-58.
>PMID: 9593818.
>
> Fischman AJ, et al.           
>Rapid detection of Parkinson's disease by SPECT with altropane: a selective
>ligand for dopamine transporters.
>Synapse. 1998 Jun; 29(2): 128-141.
>PMID: 9593103; UI: 98253935.
>
> Madras BK, et al.           
>Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human
>dopamine transporter in postmortem normal and Parkinson's diseased brain.
>Synapse. 1998 Jun; 29(2): 116-127.
>PMID: 9593102; UI: 98253934.
>
> Baldi I, et al.           
>[No title available].
>Rev Epidemiol Sante Publique. 1998 Mar; 46(2): 134-142. French.
>PMID: 9592856; UI: 98255214.
>
> Hubble JP, et al.           
>Gene-toxin interaction as a putative risk factor for Parkinson's disease with
>dementia.
>Neuroepidemiology. 1998; 17(2): 96-104.
>PMID: 9592786; UI: 98255144.
>
> Ubeda JV.           
>Null hypothesis of husband-wife concordance of Parkinson's disease in 1,000
>married couples over age 50 in Spain.
>Neuroepidemiology. 1998; 17(2): 90-95.
>PMID: 9592785; UI: 98255143.
>
> Mandel RJ, et al.           
>Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated
>Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in
>a Rat Model of Parkinson's Disease.
>J Neurosci. 1998 Jun 1; 18(11): 4271-4284.
>PMID: 9592104.
>
> Kotake Y, et al.           
>Deprenyl decreases an endogenous parkinsonism-inducing compound,
>1-benzyl-1,2,3,4-tetra-hydro-isoquinoline in mice: in vivo and in vitro
>studies.
>Brain Res. 1998 Mar 23; 787(2): 341-343.
>PMID: 9518683; UI: 98186768.
>
> Baas H, et al.           
>Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing
>off" phenomenon and levodopa requirements in fluctuating parkinsonian
>patients.
>Neurology. 1998 May; 50(5 Suppl 5): S46-S53.
>PMID: 9591522; UI: 98252196.
>
> Waters CH, et al.           
>Tolcapone in stable Parkinson's disease: efficacy and safety of long-term
>treatment. Tolcapone Stable Study Group.
>Neurology. 1998 May; 50(5 Suppl 5): S39-S45.
>PMID: 9591521; UI: 98252195.
>
> Jorga KM.           
>Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of
>early studies in volunteers.
>Neurology. 1998 May; 50(5 Suppl 5): S31-S38.
>PMID: 9591520; UI: 98252194.
>
> Goetz CG.           
>Influence of COMT inhibition on levodopa pharmacology and therapy.
>Neurology. 1998 May; 50(5 Suppl 5): S26-S30.
>PMID: 9591519; UI: 98252193.
>
> Chase TN.           
>Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
>Neurology. 1998 May; 50(5 Suppl 5): S17-S25.
>PMID: 9591518; UI: 98252192.
>
> Goetz CG.           
>Highlights of the North American and European experiences.
>Neurology. 1998 May; 50(5 Suppl 5): S15-S16.
>PMID: 9591517; UI: 98252191.
>
> Kurth MC, et al.           
>COMT inhibition: a new treatment strategy for Parkinson's disease.
>Neurology. 1998 May; 50(5 Suppl 5): S3-S14.
>PMID: 9591516; UI: 98252190.
>
> Fahn S.           
>Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
>Neurology. 1998 May; 50(5 Suppl 5): S1-S2. No abstract available.
>PMID: 9591515; UI: 98252189.
>
> Lindner MD, et al.           
>Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing
>cell line in rodent and primate models of Parkinson's disease.
>Cell Transplant. 1998 Mar; 7(2): 165-174.
>PMID: 9588598; UI: 98248012.
>
> Othberg AI, et al.           
>Trophic effect of porcine sertoli cells on rat and human ventral mesencephalic
>cells and HNT neurons in vitro.
>Cell Transplant. 1998 Mar; 7(2): 157-164.
>PMID: 9588597; UI: 98248011.
>
> Bakay RA, et al.           
>Immunological responses to injury and grafting in the central nervous system
>of nonhuman primates.
>Cell Transplant. 1998 Mar; 7(2): 109-120.
>PMID: 9588593; UI: 98248007.
>
> Vidal N, et al.           
>Morphological and functional evidence for enhanced growth and potassium-evoked
>dopamine release in striatal grafts innervated with a patchy growth pattern.
>An in oculo nigrostriatal cograft study.
>Cell Transplant. 1998 Mar; 7(2): 97-108.
>PMID: 9588592; UI: 98248006.
>
> Blanco L, et al.           
>[No title available].
>Rev Neurol. 1998 Mar; 26(151): 361-365. Spanish.
>PMID: 9585942; UI: 98247034.
>
> Fox SH, et al.           
>Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona
>reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
>Exp Neurol. 1998 May; 151(1): 35-49.
>PMID: 9582253; UI: 98250832.
>
> Mercuri NB, et al.           
>Modification of levodopa responses by deprenyl (selegiline): an electro-
>physiological and behavioral study in the rat relevant to Parkinson's disease.
>Ann Neurol. 1998 May; 43(5): 613-617.
>PMID: 9585355; UI: 98244754.
>
> Murer MG, et al.           
>Chronic levodopa is not toxic for remaining dopamine neurons, but instead
>promotes their recovery, in rats with moderate nigrostriatal lesions.
>Ann Neurol. 1998 May; 43(5): 561-575.
>PMID: 9585350; UI: 98244749.
>
> Uhl GR.           
>Hypothesis: the role of dopaminergic transporters in selective vulnerability
>of cells in Parkinson's disease.
>Ann Neurol. 1998 May; 43(5): 555-560. Review. No abstract available.
>PMID: 9585349; UI: 98244748.
>
> Fahn S.           
>Welcome news about levodopa, but uncertainty remains.
>Ann Neurol. 1998 May; 43(5): 551-554. No abstract available.
>PMID: 9585348; UI: 98244747.
>
> Zawada WM, et al.           
>Somatic cell cloned transgenic bovine neurons for transplantation in
>parkinsonian rats.
>Nat Med. 1998 May; 4(5): 569-574.
>PMID: 9585230; UI: 98244629.
>
> Lloyd GK, et al.           
>The potential of subtype-selective neuronal nicotinic acetylcholine receptor
>agonists as therapeutic agents.
>Life Sci. 1998; 62(17-18): 1601-1606.
>PMID: 9585143; UI: 98244542.
>
> Pacchetti C, et al.           
>Active music therapy and Parkinson's disease: methods.
>Funct Neurol. 1998 Jan; 13(1): 57-67.
>PMID: 9584875; UI: 98244266.
>
> Nutt JG.           
>New pharmacological and surgical therapies for Parkinson's disease.
>West J Med. 1998 Apr; 168(4): 267-268. No abstract available.
>PMID: 9584671; UI: 98245650.
>
> Ben-Shlomo Y, et al.           
>Investigation by Parkinson's Disease Research Group of United Kingdom into
>excess mortality seen with combined levodopa and selegiline treatment in
>patients with early, mild Parkinson's disease: further results of randomised
>trial and confidential inquiry.
>BMJ. 1998 Apr 18; 316(7139): 1191-1196.
>PMID: 9583926; UI: 98245965.
>
> Blaszczyk JW.           
>Motor deficiency in Parkinson's disease.
>Acta Neurobiol Exp (Warsz). 1998; 58(1): 79-93.
>PMID: 9583191; UI: 98244026.
>
> Davey GP, et al.
>Energy Thresholds in Brain Mitochondria. Potential involvement in
>neurodegeneration.
>J Biol Chem. 1998 May 22; 273(21): 12753-12757.
>PMID: 9582300.
>
> Abrams KR.           
>Monitoring randomised controlled trials. Parkinson's disease trial illustrates
>the dangers of stopping early.
>BMJ. 1998 Apr 18; 316(7139): 1183-1184. No abstract available.
>PMID: 9552993; UI: 98221041.
>
> Breteler MM.           
>Selegiline, or the problem of early termination of clinical trials. The
>clinical questions are not well answered, and probably never will be.
>BMJ. 1998 Apr 18; 316(7139): 1182-1183. No abstract available.
>PMID: 9552992; UI: 98221040.
>
> Vaughan JR, et al.           
>Sequencing of the alpha-synuclein gene in a large series of cases of familial
>Parkinson's disease fails to reveal any further mutations. The European
>Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD).
>Hum Mol Genet. 1998 Apr; 7(4): 751-753.
>PMID: 9499430; UI: 98167862.
>
> Castano A, et al.           
>Lipopolysaccharide intranigral injection induces inflammatory reaction and
>damage in nigrostriatal dopaminergic system.
>J Neurochem. 1998 Apr; 70(4): 1584-1592.
>PMID: 9580157; UI: 98181720.
>
> Gage FH.           
>Cell therapy.
>Nature. 1998 Apr 30; 392(6679 Suppl): 18-24. Review.
>PMID: 9579857; UI: 98239460.
>
> Merello M, et al.           
>Changes in the motor response to acute L-dopa challenge after unilateral
>microelectrode-guided posteroventral pallidotomy.
>Clin Neuropharmacol. 1998 Mar; 21(2): 135-138.
>PMID: 9579303; UI: 98240466.
>
> Nacasch N, et al.           
>Clozapine for the treatment of agitated-depressed patients with cognitive
>impairment: a report of three cases.
>Clin Neuropharmacol. 1998 Mar; 21(2): 132-134.
>PMID: 9579302; UI: 98240465.
>
> Lyons KE, et al.           
>Gender differences in Parkinson's disease.
>Clin Neuropharmacol. 1998 Mar; 21(2): 118-121.
>PMID: 9579298; UI: 98240461.
>
> Bedard MA, et al.           
>Attentional deficits in Parkinson's disease: partial reversibility with
>naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist.
>Clin Neuropharmacol. 1998 Mar; 21(2): 108-117.
>PMID: 9579297; UI: 98240460.
>
> Brooks DJ, et al.           
>A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole
>dopaminergic therapy in Parkinson's disease.
>Clin Neuropharmacol. 1998 Mar; 21(2): 101-107.
>PMID: 9579296; UI: 98240459.
>
> Sternic N, et al.           
>The therapeutic effect of moclobemide, a reversible selective monoamine
>oxidase a inhibitor, in Parkinson's disease.
>Clin Neuropharmacol. 1998 Mar; 21(2): 93-96.
>PMID: 9579294; UI: 98240457.
>
> Baas H, et al.           
>Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian
>patients with end-of-dose motor fluctuations.
>Clin Neuropharmacol. 1998 Mar; 21(2): 86-92.
>PMID: 9579293; UI: 98240456.
>
> Kuno S, et al.           
>Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-
>treated cynomolgus monkeys.
>Clin Neuropharmacol. 1998 Jan; 21(1): 35-40.
>PMID: 9579283; UI: 98240446.
>
> Brefel C, et al.           
>Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
>Br J Clin Pharmacol. 1998 Apr; 45(4): 412-415.
>PMID: 9578193; UI: 98237304.
>
> Seitz G, et al.           
>Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene
>expression in the human neuroblastoma cell line SK-N-SH.
>Neurosci Lett. 1998 Mar 6; 244(1): 33-36.
>PMID: 9578138; UI: 98237249.
>
> Praamstra P, et al.           
>Evidence for lateral premotor and parietal overactivity in Parkinson's disease
>during sequential and bimanual movements. A PET study.
>Brain. 1998 Apr; 121( Pt 4): 769-772. No abstract available.
>PMID: 9577401; UI: 98238262.
>
> Majsak MJ, et al.           
>The reaching movements of patients with Parkinson's disease under self-
>determined maximal speed and visually cued conditions.
>Brain. 1998 Apr; 121( Pt 4): 755-766.
>PMID: 9577399; UI: 98238260.
>
> Johnson KA, et al.           
>Bimanual co-ordination in Parkinson's disease.
>Brain. 1998 Apr; 121( Pt 4): 743-753.
>PMID: 9577398; UI: 98238259.
>
> Alberts JL, et al.           
>The co-ordination and phasing of a bilateral prehension task. The influence of
>Parkinson's disease.
>Brain. 1998 Apr; 121( Pt 4): 725-742.
>PMID: 9577397; UI: 98238258.
>
> Scott R, et al.           
>Neuropsychological, neurological and functional outcome following pallidotomy
>for Parkinson's disease. A consecutive series of eight simultaneous bilateral
>and twelve unilateral procedures.
>Brain. 1998 Apr; 121( Pt 4): 659-675.
>PMID: 9577392; UI: 98238253.
>
> Inzelberg R, et al.           
>Auditory hallucinations in Parkinson's disease.
>J Neurol Neurosurg Psychiatry. 1998 Apr; 64(4): 533-535.
>PMID: 9576549; UI: 98236086.
>
> Hayes AE, et al.           
>Toward a functional analysis of the basal ganglia.
>J Cogn Neurosci. 1998 Mar; 10(2): 178-198.
>PMID: 9555106; UI: 98223722.
>
> Zawada WM, et al.           
>Growth factors improve immediate survival of embryonic dopamine neurons after
>transplantation into rats.
>Brain Res. 1998 Mar 9; 786(1-2): 96-103.
>PMID: 9554968; UI: 98223483.
>
> Masalha R, et al.           
>Selective dopamine neurotoxicity by an industrial chemical: an environmental
>cause of Parkinson's disease? 1. [Brain research 774 (1997) 260-264].
>Brain Res. 1998 Mar 2; 785(2): 359. No abstract available.
>PMID: 9518694; UI: 98186720.
>
> de la Monte SM, et al.           
>P53- and CD95-associated apoptosis in neurodegenerative diseases.
>Lab Invest. 1998 Apr; 78(4): 401-411.
>PMID: 9564885; UI: 98224556.
>
> Kelly MA, et al.           
>Locomotor activity in D2 dopamine receptor-deficient mice is determined by
>gene dosage, genetic background, and developmental adaptations.
>J Neurosci. 1998 May 1; 18(9): 3470-3479.
>PMID: 9547254; UI: 98213724.
>
> Azizi SA, et al.           
>Engraftment and migration of human bone marrow stromal cells implanted in the
>brains of albino rats--similarities to astrocyte grafts.
>Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7): 3908-3913.
>PMID: 9520466; UI: 98188303.
>
> Almeida A, et al.           
>A rapid method for the isolation of metabolically active mitochondria from rat
>neurons and astrocytes in primary culture.
>Brain Res Brain Res Protoc. 1998 Mar; 2(3): 209-214.
>PMID: 9507134; UI: 98176023.
>
>continued in part two....
>
>janet paterson aka calendar control supervisor
>51/10 - sinemet/selegiline/prozac - [log in to unmask]
>quotations: http://newww.com/cgi-bin/do_cal?c:newvoice
>pwp event calendar: http://newww.com/cgi-bin/do_cal?c:pwpc
>
>------------------------------
>
>End of PARKINSN Digest - 27 May 1998 - Special issue
>****************************************************
>
>